TMCnet News
AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial ResultsAmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015. Corporate Update
Reflecting on the progress made to date in 2015, Jeremy Curnock Cook, Chairman of AmpliPhi said, "Over the past few months, AmpliPhi has made a number of significant advancements in reinforcing our foundation, through new appointments to the executive leadership team, continued positive progress with our planned clinical trial programs and securing critical intellectual property that will protect our platform technologies. AmpliPhi is well-positioned to move forward with plans to further establish itself as the leading phage company in the world, and I am encouraged by the exciting prospects for the year ahead." First Quarter 2015 Financial Results: As a result of the $13 million financing, the Company has significantly improved it overall liquidity and balance sheet strength in preparation for both executing on its R&D activities and preparing for an anticipated listing on a major national stock exchange.
The Company is planning to provide a mid-year corporate update via live conference call and webcast during its upcoming Annual Shareholder's Meeting on June 30, 2015 in Washington, D.C. About AmpliPhi BioSciences
AmpliPhi BioSciences Corporation (OTCQB: APHB) is a biotechnology
company focused on the development and commercialization of novel
bacteriophage-based antibacterial therapeutics. The Company's product
development programs target infections that are often resistant to
existing antibiotic treatments. AmpliPhi is collaborating with a number
of leading organizations, including Intrexon Corporation (NYSE: XON),
the U.S. Army, The Royal Brompton Clinic in London, UK and UK-based
University of Leicester, to rapidly advance bacteriophage-based
therapies. About Bacteriophage Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects. Forward Looking Statements Statements in this press release about AmpliPhi's manufacturing capabilities and ability to manufacture pure, reproducible, high quality, cost effective human preparations, the potential use of bacteriophages to treat bacterial infections, including infections in biofilms and infections that do not respond to antibiotics, and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that the Company will not be able to successfully manufacture sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi may not commence clinical trials or complete IND-enabling studies as expected, that the clinical trials will not be successful, that further development of the Company's products will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission (SEC (News - Alert)) on April 15, 2015.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150519005612/en/ |